CLOs on the Move

Kindeva Drug Delivery

www.kindevadd.com

 
Kindeva is a global force in combination drug delivery and manufacturing. Leveraging more than 100 years of innovation, Kindeva provides unrivaled expertise at every stage of pulmonary & nasal, injectable, and transdermal therapy development and manufacturing. Whether determining ideal delivery and dosage or scaling sterile manufacturing and fill-finish operations, every solution is backed by extensive technological capabilities, deep regulatory knowledge, and nine state-of-the-art facilities. Kindeva`s proactive, informed solutions minimize risk and maximize confidence from ideation through commercialization, bringing high-quality products to patients in need, faster.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
David Stevens
 Chief Operating (COO) & Commercial Officer (CCO) Profile

Similar Companies

I.C.H. Corporation

I.C.H. Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diapharma Group Inc.

Diapharma Group Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Sha Pharmaceuticals

Sha Pharmaceuticals is a Pelham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axm Pharma

AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal

Visus Therapeutics

Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.